The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The market for non-alcoholic steatohepatitis (NASH) has seen remarkable growth in recent years and is poised for even greater expansion. This blog delves into the factors driving this growth, key trends, and the major players shaping the future of NASH treatment.

Rapid Market Expansion
Historic Growth

2023 Market Size: $3.33 billion

2024 Projection: $4.54 billion

CAGR: 36.3%

The historic growth of the NASH market can be attributed to:

Rising prevalence of NASH

Obesity epidemic

Growing awareness and diagnoses

Shift in lifestyle and dietary patterns

Healthcare infrastructure development

View More On The Non-Alcoholic Steatohepatitis (NASH) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

Future Growth
2028 Projection: $14.53 billion

CAGR: 33.7%

Key drivers for future growth include:

Advancements in NASH drug development

Increasing NASH screening initiatives

Rising healthcare expenditure

Collaborative research efforts

Government support and regulations

Key Trends in the NASH Market
Technological Advances

Technological innovation is a major trend in the NASH market. Companies are focusing on developing advanced diagnostic tools and treatments.

Example: In May 2021, GENFIT Inc. launched NASHnext, a non-invasive test for diagnosing NASH using the NIS4TM screening technology.

Lifestyle Interventions and Patient Education

There is a growing emphasis on lifestyle changes and educating patients about NASH.

Focus on lifestyle interventions

Increased patient education programs

Regulatory Advancements

Regulatory support is playing a crucial role in market growth.

 

New pathway designations

Streamlined approval processes

Integration of AI

Artificial intelligence is being increasingly used for diagnosis and monitoring of NASH.

 

AI tools for early detection

AI-driven monitoring systems

The Impact of the Obesity Epidemic

Rising Obesity Rates

The obesity epidemic is a significant factor driving the demand for NASH treatments.

 

Obesity Statistics: According to the World Obesity Federation, over 60% of US adults were overweight in 2021. Projections indicate that obesity rates could reach 44.2% for men and 44.4% for women by 2025.

NASH and Obesity

The increasing prevalence of obesity leads to higher rates of non-alcoholic fatty liver disease (NAFLD) and subsequently NASH, necessitating effective treatments.

 

NASH as a leading cause of severe liver disease

Growing need for NASH drugs and treatments

Major Players in the NASH Market
Several key companies are driving innovation and growth in the NASH market:

NGM Biopharmaceuticals Inc.

Novartis AG

AstraZeneca plc.

GlaxoSmithKline plc.

1. Hoffmann-La Roche AG

The Takeda Pharmaceutical Company Limited

Gilead Sciences Inc.

Novo Nordisk A/S

Genfit SA

Intercept Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc.

Blade Therapeutics Inc.

Cempra Pharmaceuticals Inc.

Galmed Pharmaceuticals Inc.

Strategic Acquisitions
Advanz Pharma’s Acquisition of Intercept Pharmaceuticals

In July 2022, Advanz Pharma acquired Intercept Pharmaceuticals, aiming to enhance its presence in rare disease treatments.

Objective: To leverage the orphan medicine Ocaliva (obeticholic acid) for treating primary biliary cholangitis (PBC).

Market Segmentation
The NASH market is segmented into various types, products, disease causes, sales channels, and applications:

Type: Solid, Liquid

Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

Application: Oral, Parenteral

Regional Insights
North America

North America was the largest region in the NASH market share in 2023, driven by robust healthcare infrastructure and high obesity rates.

The non-alcoholic steatohepatitis (NASH) market is experiencing unprecedented growth, fueled by technological advancements, rising obesity rates, and strategic industry moves. As awareness and diagnosis of NASH increase, the market is set to expand significantly, offering new opportunities and challenges for stakeholders.

Request A Sample Of The Global Non-Alcoholic Steatohepatitis (NASH) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=8805&type=smp